Mangafodipir

Drug Profile

Mangafodipir

Alternative Names: mangafodipir trisodium; MnDPDP; PP-099; S 095; Teslascan; WIN 59010

Latest Information Update: 03 Mar 2016

Price : $50

At a glance

  • Originator GE Healthcare
  • Developer GE Healthcare; PledPharma
  • Class Acetates; Anti-ischaemics; Contrast media; Ethylenediamines; Pyridines; Small molecules
  • Mechanism of Action Antioxidants; Iron chelating agents; Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Myocardial infarction
  • Market Withdrawal Liver disorders
  • Discontinued Neutropenia

Most Recent Events

  • 29 Feb 2016 PledPharm receives patent for PLED compounds for their anti-cancer effect by the European Patent Office
  • 29 Feb 2016 PledPharm receives use patent for PLED compounds by authorities in Canada, Russia, Mexico, Japan and Australia
  • 10 Sep 2015 Phase-II development for Myocardial infarction is ongoing in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top